Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGP Products Operations GmbH
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/748,566external-prioritypatent/US6528090B2/en
Application filed by Abbott LaboratoriesfiledCriticalAbbott Laboratories
Publication of CA2341803A1publicationCriticalpatent/CA2341803A1/en
Application grantedgrantedCritical
Publication of CA2341803CpublicationCriticalpatent/CA2341803C/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Medicinal Preparation
(AREA)
Abstract
A new oral polymeric controlled release formulation suitable for the once-a- day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
CA002341803A2000-12-222001-03-23Controlled release formulation of divalproex sodium
Expired - LifetimeCA2341803C
(en)